Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration
Status:
Completed
Trial end date:
2021-03-23
Target enrollment:
Participant gender:
Summary
The pharmacokinetics of fluconazole are expected to be different in obese patients compared
to non-obese patients. The investigators will determine fluconazole and free fluconazole
concentrations in 16 obese patients and 8 healthy volunteers, who will receive oral and
intravenous fluconazole in a semi-simultaneous design.
A full pharmacokinetic curve will be obtained until 48 hours after intravenous
administration.